Fennec Pharmaceuticals INC Form 4 insider transactions

Director Rosty Raykov acquired 25,000 common shares of Fennec Pharmaceuticals through option exercise at a price of $2.69 on December 20, 2024.

A Fennec Pharmaceuticals director, Rosty Raykov, sold 796 common shares at $6.04 per share on December 5, 2024, under a pre-arranged 10b5-1 trading plan.

Director Rosty Raykov of Fennec Pharmaceuticals reported acquiring 2,431 shares through the release of restricted stock and selling 1,635 shares under a pre-arranged 10b5-1 plan.

Fennec Pharmaceuticals' Chief Financial Officer, Robert Andrade, acquired 1,042 common shares through the vesting of restricted stock.

A Fennec Pharmaceuticals director, Chris A Rallis, exercised options to acquire 10,000 shares and sold 6,409 shares to cover tax obligations.

Fennec Pharmaceuticals' Chief Financial Officer, Robert Andrade, exercised stock options to acquire 15,816 common shares at $2.45 per share.

Christiana Cioffi, Chief Strategy Officer of Fennec Pharmaceuticals, was granted 150,000 incentive stock options on November 13, 2024.

Fennec Pharmaceuticals' Chief Commercial Officer, Terry L. Evans, was granted incentive stock options for 150,000 common shares on November 13, 2024.

Fennec Pharmaceuticals' Chief Medical Officer, Pierre Sayad, was granted 150,000 stock options on November 13, 2024, under the company's 2020 Equity Incentive Plan.

Director Rosty Raykov of Fennec Pharmaceuticals reports the sale of 2,431 common shares at $4.31 per share, alongside the release of restrictions on 2,431 previously awarded shares.

Robert Andrade, CFO of Fennec Pharmaceuticals, reports the acquisition of 1,042 common shares on October 31, 2024.

Director Chris A. Rallis of Fennec Pharmaceuticals exercised stock options and sold a portion of the acquired shares to cover tax obligations, as disclosed in a recent SEC filing.

Robert Andrade, CFO of Fennec Pharmaceuticals, reports the release of 1,042 common shares from restriction on September 30, 2024.

Director Rosty Raykov of Fennec Pharmaceuticals reports the sale of 2,431 common shares at $4.94 per share on October 1, 2024, pursuant to a pre-arranged 10b5-1 trading plan.

Director Rosty Raykov of Fennec Pharmaceuticals reports the sale of 2,431 common shares on September 4, 2024, following the release of restricted shares.

Robert Andrade, CFO of Fennec Pharmaceuticals, reports the acquisition of 1,042 common shares on August 31, 2024.

Director Rosty Raykov amends a previous Form 4 filing to accurately reflect a donation of 26,001 common shares to charity.

Director Rosty Raykov of Fennec Pharmaceuticals Inc. [FENC] donated a portion of his common shares to charity on August 23, 2024.

Director Khalid Islam of Fennec Pharmaceuticals was granted a non-qualified stock option to purchase 25,000 shares of the company's common stock on August 15, 2024.

Director Jodi Cook was granted stock options to purchase 20,000 shares of Fennec Pharmaceuticals on August 15, 2024.

Marco Maria Brughera, a director of Fennec Pharmaceuticals, was granted a stock option to purchase 20,000 shares of the company's common stock on August 15, 2024.

Director Chris Rallis of Fennec Pharmaceuticals was granted a stock option to purchase 20,000 shares of the company's common stock on August 15, 2024.

Fennec Pharmaceuticals' CEO, Jeffrey S. Hackman, was granted incentive stock options to purchase 400,000 shares of the company's common stock on August 15, 2024.

Robert Andrade, CFO of Fennec Pharmaceuticals, reports the acquisition of 1,042 common shares on July 31, 2024.

Fennec Pharmaceuticals CEO Rostislav Raykov reports the sale of 2,431 common shares at $6.255 per share, pursuant to a pre-arranged 10b5-1 trading plan.

Chris A. Rallis, a director of Fennec Pharmaceuticals, exercised options to acquire 1,792 shares at $2.79 each and sold 1,173 shares at $6.03 to cover tax obligations.

Fennec Pharmaceuticals CEO Rosty Raykov reports the acquisition and disposal of common shares, including shares sold under a 10b5-1 plan.

Robert Andrade, CFO of Fennec Pharmaceuticals, reports the acquisition and disposal of common shares on July 1, 2024.

Robert Andrade, CFO of Fennec Pharmaceuticals, reports the acquisition of 1,042 common shares on May 31, 2024.

Fennec Pharmaceuticals CEO Rostislav Raykov reports the sale of 2,431 common shares at $6.76 each, executed under a pre-arranged 10b5-1 trading plan.